Premium
EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Author(s) -
Pettitt A.R.,
Kalakonda N.,
Polydoros F.,
Bickerstaff M.,
Me G.,
Coupland S.E.,
Oates M.,
Lin K.,
Pocock C.,
Jenkins S.,
Schuh A.,
Wandroo F.,
Rassam S.,
Duncombe A.S.,
Jenner M.,
Cervi P.,
Paneesha S.,
Aldouri M.,
Fox C.P.,
Knechtli C.,
Hamblin M.,
Turner D.,
Hillmen P.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_77
Subject(s) - ofatumumab , idelalisib , bendamustine , obinutuzumab , medicine , placebo , chlorambucil , fludarabine , rituximab , chemotherapy , cyclophosphamide , chronic lymphocytic leukemia , ibrutinib , lymphoma , leukemia , alternative medicine , pathology